Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future.
PURPOSE: This research study is collecting and storing blood and tissue samples from patients being evaluated for hematologic cancer.
|Condition or Disease||Intervention/Treatment||Phase|
Provide source of patient tissue, blood, and body fluid samples for ongoing diagnostic, prognostic, or immune-monitoring studies.
Support and enhance translational, clinical and basic research for Lineberger Comprehensive Cancer Center (LCCC) members (and non-members who have an LCCC member as sponsor and collaborator) with IRB-approved studies.
Maintain responsible and appropriate policies and procedures that ensure good patient care and responsible conduct of research.
Address medical and legal issues, and protect participant and patient privacy and confidentiality.
Provide a responsible and uniform mechanism for the integrated coordination of the hemato-pathologist and surgeon or hematology/oncology staff, researcher, and protocol office to obtain appropriate specimens for researchers.
Support young investigators to obtain pilot data for grant funding.
OUTLINE: Patients undergo tissue, blood, and body fluid collection during diagnostic or routine procedures for future correlative studies. Tissue samples may include, but are not limited to, lymph node or non-nodal biopsies, bone marrow biopsy and/or aspirate, blood and serum, and buccal swabs for germline DNA analysis.
Primary Outcome Measures
- Tissue, blood, and body fluid samples collection for ongoing diagnostic, prognostic, or immune-monitoring studies [30 years]
- Development of a centralized, quality-controlled, quality-assured facility for the procurement, processing, storage, and distribution of normal and malignant tissue specimens and corresponding blood specimens [30 years]
Diagnosis of abnormal hematopoietic/lymphoid cancer, including any of the following:
Acute myeloid leukemia
Acute lymphoblastic leukemia
Chronic myelogenous leukemia
Chronic lymphoid leukemia
Any other diseases that generate abnormalities in either number, function, or both of any cell type of hematolymphoid lineage
Patients who are being evaluated at the hematology/oncology clinics of the University of North Carolina Hospitals, at the stem cell transplant clinic, or in the hospital
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Contacts and Locations
|1||Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill||Chapel Hill||North Carolina||United States||27599-7295|
Sponsors and Collaborators
- UNC Lineberger Comprehensive Cancer Center
- National Cancer Institute (NCI)
- Principal Investigator: Paul Armistead, MD, UNC Lineberger Comprehensive Cancer Center
Study Documents (Full-Text)None provided.
- LCCC 0824